Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00100
|
|||||
Drug Name |
Adenosine monophosphate
|
|||||
Synonyms |
(S)-1-C-(7-Amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-D-ribitol, 5-(dihydrogen phosphate); 1H-Pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-D-ribofuranosyl-, 5'-(dihydrogen phosphate)-, hydrate; 5'-AMP; 5'-Adenylic acid, homopolymer; 5'-Deoxy-5'-thioadenosine 5'-monophosphate; 5'-O-phosphonatoadenosine; 5'-O-phosphonoadenosine; 5'-Thio-5'-adenylic acid; 5'-adenosine monophosphate; 5'-adenylic acid; 7-Amino-3-beta-D-ribofuranosyl-1H-pyrazolo(4,3-d)pyrimidine 5'-(dihydrogen phosphate) hydrate; 7A8E6D15-9136-44C1-88C9-E1A224638E56; 7gpb; 8-Aminoadenosine 5'-monophosphate; 8gpb; A-5mp; ADENOSINE-5'-PHOSPHATE; AMP; AMP (VAN); AMP (nucleotide); AMP dianion; ASMP; Adenine polynucleotides; Adenosine 5'-(dihydrogen phosphate); Adenosine 5'-monophosphate; Adenosine 5'-monophosphoric acid; Adenosine 5'-phosphate; Adenosine 5'-phosphoric acid; Adenosine Monophosphate (Amp); Adenosine phosphate; Adenosine phosphate (USAN/INN); Adenosine phosphate [USAN:BAN:INN]; Adenosine phosphate [USAN:INN:BAN]; Adenosine, mono(dihydrogen phosphate) (ester); Adenosine-5'-monophosphate; Adenosine-5'-monophosphoric acid; Adenosine-5'P; Adenosine-5-monophosphate dianion; Adenosine-5-monophosphate(2-); Adenosine-5-monophosphoric acid; Adenosine-5-phosphate; Adenosine-monophosphate; Adenosine-phosphate; Adenosini phosphas; Adenosini phosphas [INN-Latin]; Adenovite; Adenyl; Adenyl (TN);Adenylic acid (VAN); Adenylate; Adenylic acid; Ado5'P; Cardiomone; Ergadenylic acid; Formycin 5'-monophosphate hydrate; Formycin 5'-phosphate; Formycin 5'-phosphate hydrate; Formycin A 5'-monophosphate hydrate; Fosfato de adenosina; Fosfato de adenosina [INN-Spanish]; GAMMA-ARSONO-BETA, GAMMA-METHYLENEADENOSINE-5'-DIPHOSPHATE; Lycedan; Monophosphadenine; Muscle adenylic acid; Muskeladenosin-phosphorsaeure; Muskeladenylsaeure; My-B-Den; Myoston; PAdo; POLY A; Phosaden; Phosphaden; Phosphate d'adenosine; Phosphate d'adenosine [INN-French]; Phosphentaside; Polyadenylic acids; Vitamin B8; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Dietary shortage [ICD11: 5B7Z] | Approved | [1] | |||
Therapeutic Class |
Dietary supplement
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C10H14N5O7P
|
|||||
Canonical SMILES |
C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)O)O)O)N
|
|||||
InChI |
InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
|
|||||
InChIKey |
UDMBCSSLTHHNCD-KQYNXXCUSA-N
|
|||||
CAS Number |
CAS 61-19-8
|
|||||
Pharmaceutical Properties | Molecular Weight | 347.22 | Topological Polar Surface Area | 186 | ||
Heavy Atom Count | 23 | Rotatable Bond Count | 4 | |||
Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 11 | |||
XLogP |
-3.5
|
|||||
PubChem CID | ||||||
PubChem SID |
3322
, 583720
, 583923
, 584440
, 584442
, 584452
, 584455
, 584487
, 584571
, 585427
, 610407
, 819401
, 819945
, 819947
, 819949
, 820210
, 820387
, 820906
, 821396
, 823646
, 823841
, 824145
, 824148
, 826522
, 826525
, 826568
, 826569
, 827049
, 827589
, 827693
, 827918
, 828361
, 828365
, 828366
, 828368
, 828899
, 830720
, 830875
, 832127
, 832329
, 832477
, 832865
, 833689
, 834616
, 836112
, 837134
, 838177
, 838245
, 838945
, 841545
|
|||||
ChEBI ID |
ChEBI:16027
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | PMP34 | Transporter Info | Peroxisomal membrane protein PMP34 | Substrate | [2] | |
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | PMP34 | Transporter Info | Km = 190 microM | Human liver cancer cells (HepG2)-PMP34 | [2] | |
References | ||||||
1 | Bitter blocker backed by FDA | |||||
2 | The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. Biochem J. 2012 Apr 1;443(1):241-7. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.